69491-59-4

Basic information

• Product Name: 3-PYRIMIDIN-5-YLANILINE
• Synonyms: 3-(5-PYRIMIDINYL)ANILINE;3-PYRIMIDIN-5-YLANILINE;AKOS BAR-1329;Benzenamine, 3-(5-pyrimidinyl)- (9CI)
• CAS NO: 69491-59-4
• Molecular Formula: C₁₀H₉N₃
• Molecular Weight: 171.2
• Product Categories: QUINAZOLINE
• Mol File: 69491-59-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 163-166°C
• Boiling Point: 389.9°C at 760 mmHg
• Flash Point: 218°C
• Appearance: /
• Density: 1.193g/cm³
• Vapor Pressure: 2.76E-06mmHg at 25°C
• Refractive Index: 1.633
• CAS DataBase Reference: 3-PYRIMIDIN-5-YLANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-PYRIMIDIN-5-YLANILINE(69491-59-4)
• EPA Substance Registry System: 3-PYRIMIDIN-5-YLANILINE(69491-59-4)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38-36-22
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 69491-59-4(Hazardous Substances Data)

Usage

General Description

3-Pyrimidin-5-ylaniline is a chemical compound with a molecular formula C11H9N3. It consists of a pyrimidine ring fused to an aniline moiety. 3-PYRIMIDIN-5-YLANILINE is used in the preparation of pharmaceuticals, agrochemicals, and organic materials. It has potential applications as an intermediate in the synthesis of various bioactive compounds, including kinase inhibitors and anticancer agents. 3-Pyrimidin-5-ylaniline is an important building block in organic chemistry and has diverse applications in the field of medicinal and agricultural chemistry.

InChI:InChI=1/C10H9N3/c11-10-3-1-2-8(4-10)9-5-12-7-13-6-9/h1-7H,11H2

Upstream product

• 4595-59-9 5-bromopyrimidine 
• 591-19-5 m-Bromoaniline 
• 109299-78-7 pyrimidine 5-boronic acid 
• 626-01-7 3-Iodoaniline 
• 69491-54-9 5‐(3‐nitrophenyl)pyrimidine 
• 13331-27-6 m-nitrobenzene boronic acid 

Downstream Products

• 333792-44-2 N-[3-(pyrimidin-5-yl)phenyl]-9H-fluorene-1-carboxamide 
• 333792-99-7 N-[3-(pyrimidin-5-yl)-phenyl]-3-methyl-2-trifluoromethyl-1H-indole-7-carboxamide 
• 333792-78-2 N-(3-(pyrimidin-5-yl)-phenyl)-9H-carbazole-1-carboxamide 
• 333793-09-2 N-(3-(pyrimidin-5-yl)-phenyl)-2,3-dimethyl-1H-indole-7-carboxamide 
• 1388657-44-0 2-chloro-N-(3-pyrimidin-5-yl-phenyl)acetamide 
• 184173-95-3 N-Acetyl 3-(5-pyrimidyl)aniline 
• 374555-37-0 (5-bromoisoquinolin-1-yl)-[3-(pyrimidin-5-yl)phenyl]amine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6

The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.

Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution

Allosteric modulators of the cannabinoid CB1 receptor have recently been reported as an alternative approach to modulate the CB1 receptor for therapeutic benefits. In this study, we report the design and synthesis of a series of diarylureas derived from PSNCBAM-1 (2). Similar to 2, these diarylureas dose-dependently inhibited CP55,940-induced intracellular calcium mobilization and [35S]GTP-γ-S binding while enhancing [3H]CP55,940 binding to the CB1 receptor. Structure-activity relationship studies revealed that the pyridinyl ring of 2 could be replaced by other aromatic rings and the pyrrolidinyl ring is not required for CB1 allosteric modulation. 34 (RTICBM-74) had similar potencies as 2 in all in vitro assays but showed significantly improved metabolic stability to rat liver microsomes. More importantly, 34 was more effective than 2 in attenuating the reinstatement of extinguished cocaine-seeking behavior in rats, demonstrating the potential of this diarylurea series as promising candidates for the development of relapse treatment of cocaine addiction.

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.